Trial · NCT03181503
Results by group242
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 242
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 12 | -23.0 | Standard Deviation 26.31 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 12 | -62.6 | Standard Deviation 34.98 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 16 | -25.9 | Standard Deviation 24.89 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 16 | -62.4 | Standard Deviation 35.93 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 18 | -26.2 | Standard Deviation 25.39 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 18 | -60.4 | Standard Deviation 36.15 | Percent change |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 1 | -0.5 | Standard Deviation 0.82 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 1 | -1.9 | Standard Deviation 1.47 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 2 | -0.8 | Standard Deviation 1.14 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 2 | -3.2 | Standard Deviation 2.03 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 4 | -1.3 | Standard Deviation 1.41 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 4 | -3.9 | Standard Deviation 2.44 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 8 | -1.9 | Standard Deviation 1.80 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 8 | -4.2 | Standard Deviation 2.60 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 12 | -1.8 | Standard Deviation 2.05 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 12 | -4.6 | Standard Deviation 2.71 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 16 | -2.0 | Standard Deviation 1.97 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 16 | -4.6 | Standard Deviation 2.86 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 18 | -2.1 | Standard Deviation 2.02 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 18 | -4.5 | Standard Deviation 2.94 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03181503/results?page=3